(WEHT) — A Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic COVID-19 in adults has begun.
The trial, which will be conducted at U.S. clinical research sites, is expected to enroll approximately 30,000 adult volunteers who do not have COVID-19.
The mRNA-1273 vaccine candidate will be tested at approximately 89 clinical research sites in the United States.
Dr. Anthony Fauci, Director of NIAID of the National Institute of Health, discusses the clinical trial process and what Americans can do to volunteer in the video above.
To enroll in the vaccine trials, visit coronaviruspreventionnetwork.org.
(This story was originally published on August 3, 2020)
LATEST CORONAVIRUS NEWS:
- USI student confirms COVID-19 cases in fraternity
- Congress still can’t compromise on a COVID-19 relief bill
- What experts say about Indiana’s low spread rate
- Traveling COVID-19 testing unit launching in western Kentucky
- 28 student-athletes, four coaches quarantine after two COVID-19 cases reported in Catholic Diocese of Evansville school